In two studies run in parallel, testing different strategies, automatic referral to a pharmacist was superior to EHR alerts for increasing statin prescriptions for at-risk patients.
The prevalence of elevated low-density lipoprotein cholesterol has declined recently, but millions of Americans still have levels for which treatment is recommended or should be considered and many remain untreated.
The latest study of statins and diabetes risk points to a small increased risk for new-onset diabetes with rosuvastatin vs atorvastatin, but experts advise caution in interpreting the results.
Neurologist Jeremy Chataway brings you the latest on important clinical trials in progressive MS that will help guide the field toward better treatments.